Ep. 136 - IRA, KRAS & ESMO

BioCentury This Week

Biopharma executives and investors are bracing for the impact of the newly passed Inflation Reduction Act. On the latest BioCentury This Week podcast, BioCentury's editors discuss pharma CEOs’ warnings that the law will reduce incentives for small molecule drug development, how biotech VCs may adjust deployment of their funds and how the government could implement the law.Turning to readouts from the European Society of Medical Oncology Congress, the BioCentury podcast team explains why the latest data for Amgen's Lumakras could shake up the KRAS inhibitor race and how Chinese investigator-initiated trials are accelerating CAR T innovation.

Reach us by sending a text

2022-09-12 22 min 5 chapters

Available Results

Generated results are saved to the knowledge database for reuse and search.

No generated results are available for this episode yet.

Extract Knowledge

Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.

Generated results for public episodes are saved to the knowledge database so they can be reused and searched later.
No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in